Literature DB >> 31021377

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade.

Diwakar Davar1, John M Kirkwood1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31021377     DOI： 10.1001/jamaoncol.2019.0413

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  10 in total

Review 1.  Deciphering the Dynamic Complexities of the Liver Microenvironment - Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI).

Authors:  Tao Wang; Matthew M Yeh; Mark I Avigan; Lorraine Pelosof; Gerald M Feldman
Journal:  AAPS J       Date:  2021-08-16       Impact factor: 4.009

Review 2.  Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.

Authors:  Liangliang Xu; Chang Zou; Shanshan Zhang; Timothy Shun Man Chu; Yan Zhang; Weiwei Chen; Caining Zhao; Li Yang; Zhiyuan Xu; Shaowei Dong; Hao Yu; Bo Li; Xinyuan Guan; Yuzhu Hou; Feng-Ming Kong
Journal:  J Hematol Oncol       Date:  2022-07-07       Impact factor: 23.168

Review 3.  Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.

Authors:  Tao Wang; Desirée Denman; Silvia M Bacot; Gerald M Feldman
Journal:  Biomedicines       Date:  2022-05-20

4.  Development of an Oncogenic Driver Alteration Associated Immune-Related Prognostic Model for Stage I-II Lung Adenocarcinoma.

Authors:  Jian-Zhao Xu; Chen Gong; Zheng-Fu Xie; Hua Zhao
Journal:  Front Oncol       Date:  2021-01-28       Impact factor: 6.244

5.  Analysis of the differences in lung cancer research trends between China and the United States based using project funding data.

Authors:  Yuansheng Zheng; Yiwei Huang; Yunyi Bian; Yajing Du; Tao Lu; Qihai Sui; Ming Li; Zhencong Chen; Cheng Zhan; Junjie Xi; Wei Jiang; Qun Wang
Journal:  Ann Transl Med       Date:  2021-02

6.  Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice.

Authors:  Shalom Lerrer; Adam Mor
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

7.  Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients.

Authors:  Alexandre Gérard; Jerome Doyen; Henri Montaudié; Barbara Seitz-Polski; Marion Cremoni; Laurent Bailly; Kevin Zorzi; Caroline Ruetsch-Chelli; Vesna Brglez; Alexandra Picard-Gauci; Laura Troin; Vincent L M Esnault; Thierry Passeron
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

8.  A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients.

Authors:  Qing Liu; Yanni Lou; Liya Li; Guowang Yang; Huijuan Cui; Zhiqiang Cheng; Yuan Li; Meng Liu; Chao Deng; Donggui Wan; Yongxia Yan; Liqun Jia
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.279

Review 9.  Role of exosomal microRNAs in lung cancer biology and clinical applications.

Authors:  Chengping Hu; Silke Meiners; Christina Lukas; Georgios T Stathopoulos; Jie Chen
Journal:  Cell Prolif       Date:  2020-05-11       Impact factor: 6.831

10.  RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity.

Authors:  Ephraim A Ansa-Addo; Huai-Cheng Huang; Brian Riesenberg; Supinya Iamsawat; Davis Borucki; Michelle H Nelson; Jin Hyun Nam; Dongjun Chung; Chrystal M Paulos; Bei Liu; Xue-Zhong Yu; Caroline Philpott; Philip H Howe; Zihai Li
Journal:  Sci Adv       Date:  2020-05-29       Impact factor: 14.136
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.